Ahmedabad-based Troikaa Pharmaceuticals, has launched anti-eczema herbal medicine in collaboration with city-based non government organisation "" Society for Research and Initiatives for Sustainable Technologies and Institutions (SRISTI). |
P N Sharma, general manager of product management, told reporters at the launch of the product, "The product is researched by SRISTI and its innovators at the grassroots level." |
The anti-eczema herbal drug has been developed by SRISTI along with the local farmers having know-how of local bio-diversity and its medicinal applications. |
The anti-eczema herbal drug will be marketed under the brand name 'Herbavate' and will be sold in tubes. The drug reportedly has effective properties against eczema and a variety of inflammatory as well as infectious skin disorders. |
Almost 10-20 per cent of the world population is said to be affected by eczema that can affect all age groups. Eczema is also known as dermatitis is an inflammationary skin disorder which may cause dryness, flakiness, heat, and itching. |
Anil Gupta, head of SRISTI, said, "We have brought forth the ancient knowledge of herbal medicine by encouraging innovators found in grassroots level in villages." |
He further said that their organisation has also filed for patent of the its anti-eczema drug. He also mentioned that farmers who are the grassroots innovators will also be benefited by this as they will get some fund for their innovation from the sale of the product. |
The company expects to sell around 40,000 to 50,000 tubes during the initial months which is expected to increase upto five lakh tubes per months. "We expect to sell 60 lakh tubes per annum," said Sharma. |
Sharma also said that the anti-eczema drug market is worth Rs 150 to Rs 200 crore in India. The company is targeting the entire Indian market as eczema is a common disease in the country. At the international market company plans to target the Western countries. |